Acrivon Therapeutics, Inc.

Acrivon Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing precision medicines. The company utilizes its proprietary Generative Phosphoproteomics Acrivon Predictive Precision Proteomics, or AP3, platform. This platform is designed to quantify compound-specific, drug-regulated pathway activity levels within intact cells in an unbiased manner, generating terabytes of proprietary data and providing rapid, actionable insights. The name "Acrivon" is derived from Greek for "accurate" or "precise," reflecting the platform's ability to match therapies with patients who will benefit. Acrivon's approach aims to overcome the limitations of genetics-based precision medicine, which currently addresses less than 10% of cancer patients with easily identifiable genetic mutations. The AP3 platform is engineered to measure compound-specific effects on the entire tumor cell protein, signaling network, and drug-induced resistance mechanisms in an unbiased, modality, and disease-agnostic way. This proteomics-based approach directly measures critical tumor-driving pathways, independent of underlying genetic alterations. Acrivon believes its method is applicable across drug development stages and therapeutic modalities, not limited to cancers driven by single gene driver mutations or susceptible to a synthetic lethal approach. The company believes its method is broadly applicable to the majority of cancers, particularly solid tumors, where genetics-based approaches have often been insufficient to identify patient responders. The AP3 platform is designed to enable the therapeutic addressing of a much larger percentage of tumors by using agents attuned to specific biochemical signaling pathways.